vs
Side-by-side financial comparison of CRYO CELL INTERNATIONAL INC (CCEL) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
SOLESENCE, INC. is the larger business by last-quarter revenue ($12.5M vs $7.8M, roughly 1.6× CRYO CELL INTERNATIONAL INC). SOLESENCE, INC. runs the higher net margin — 1.3% vs -48.7%, a 50.0% gap on every dollar of revenue. On growth, SOLESENCE, INC. posted the faster year-over-year revenue change (-0.7% vs -2.3%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs -0.1%).
Cryo-Cell International, Inc. is a cord blood bank. It was founded by Dan Richard in 1989. Cryo-Cell International is the first private cord blood bank to separate and store stem cells. Cryo-Cell is headquartered outside of Tampa, in Oldsmar, Florida. In January 1997, the Company's stock began trading on the NASDAQ Small Cap market under symbol CCEL.
CCEL vs SLSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.8M | $12.5M |
| Net Profit | $-3.8M | $163.0K |
| Gross Margin | 77.9% | 27.5% |
| Operating Margin | -50.6% | 1.5% |
| Net Margin | -48.7% | 1.3% |
| Revenue YoY | -2.3% | -0.7% |
| Net Profit YoY | -105.1% | 129.2% |
| EPS (diluted) | $-0.46 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.8M | $12.5M | ||
| Q3 25 | $7.8M | $14.6M | ||
| Q2 25 | $7.9M | $20.4M | ||
| Q1 25 | $8.0M | $14.6M | ||
| Q4 24 | $8.0M | $12.6M | ||
| Q3 24 | $8.1M | $16.9M | ||
| Q2 24 | $8.0M | $13.0M | ||
| Q1 24 | $7.9M | $9.9M |
| Q4 25 | $-3.8M | $163.0K | ||
| Q3 25 | $749.4K | $-1.1M | ||
| Q2 25 | $355.8K | $2.7M | ||
| Q1 25 | $282.9K | $80.0K | ||
| Q4 24 | $-1.9M | $-559.0K | ||
| Q3 24 | $1.1M | $3.0M | ||
| Q2 24 | $655.8K | $856.0K | ||
| Q1 24 | $556.2K | $893.0K |
| Q4 25 | 77.9% | 27.5% | ||
| Q3 25 | 77.0% | 23.1% | ||
| Q2 25 | 76.6% | 28.9% | ||
| Q1 25 | 75.1% | 23.1% | ||
| Q4 24 | 78.4% | 22.0% | ||
| Q3 24 | 73.6% | 36.2% | ||
| Q2 24 | 74.8% | 28.7% | ||
| Q1 24 | 73.7% | 36.3% |
| Q4 25 | -50.6% | 1.5% | ||
| Q3 25 | 24.3% | -5.4% | ||
| Q2 25 | 18.8% | 9.4% | ||
| Q1 25 | 13.3% | 1.8% | ||
| Q4 24 | -1.5% | -1.8% | ||
| Q3 24 | 17.2% | 19.0% | ||
| Q2 24 | 17.3% | 8.0% | ||
| Q1 24 | 10.5% | 11.3% |
| Q4 25 | -48.7% | 1.3% | ||
| Q3 25 | 9.6% | -7.7% | ||
| Q2 25 | 4.5% | 13.1% | ||
| Q1 25 | 3.5% | 0.5% | ||
| Q4 24 | -23.2% | -4.4% | ||
| Q3 24 | 13.0% | 18.1% | ||
| Q2 24 | 8.2% | 6.6% | ||
| Q1 24 | 7.1% | 9.0% |
| Q4 25 | $-0.46 | $0.00 | ||
| Q3 25 | $0.09 | $-0.02 | ||
| Q2 25 | $0.04 | $0.04 | ||
| Q1 25 | $0.03 | $0.00 | ||
| Q4 24 | $-0.23 | $0.00 | ||
| Q3 24 | $0.13 | $0.04 | ||
| Q2 24 | $0.08 | $0.01 | ||
| Q1 24 | $0.07 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.3M | $1.3M |
| Total DebtLower is stronger | $8.4M | — |
| Stockholders' EquityBook value | $-18.6M | $17.6M |
| Total Assets | $61.7M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3M | $1.3M | ||
| Q3 25 | $3.2M | $429.0K | ||
| Q2 25 | $4.4M | $4.1M | ||
| Q1 25 | $3.5M | $1.8M | ||
| Q4 24 | $3.5M | $1.4M | ||
| Q3 24 | $2.1M | $2.9M | ||
| Q2 24 | $1.5M | $2.4M | ||
| Q1 24 | $979.6K | $2.0M |
| Q4 25 | $8.4M | — | ||
| Q3 25 | $8.4M | — | ||
| Q2 25 | $8.4M | — | ||
| Q1 25 | $8.5M | — | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $8.5M | — | ||
| Q2 24 | $8.5M | — | ||
| Q1 24 | $8.6M | — |
| Q4 25 | $-18.6M | $17.6M | ||
| Q3 25 | $-14.8M | $17.2M | ||
| Q2 25 | $-15.6M | $18.2M | ||
| Q1 25 | $-14.7M | $15.2M | ||
| Q4 24 | $-13.2M | $14.9M | ||
| Q3 24 | $-9.6M | $15.2M | ||
| Q2 24 | $-10.7M | $11.9M | ||
| Q1 24 | $-10.3M | $5.0M |
| Q4 25 | $61.7M | $50.1M | ||
| Q3 25 | $63.2M | $54.0M | ||
| Q2 25 | $64.4M | $60.0M | ||
| Q1 25 | $64.4M | $57.0M | ||
| Q4 24 | $64.7M | $50.0M | ||
| Q3 24 | $62.9M | $48.0M | ||
| Q2 24 | $62.6M | $40.8M | ||
| Q1 24 | $61.7M | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.3M | $1.8M |
| Free Cash FlowOCF − Capex | $1.2M | — |
| FCF MarginFCF / Revenue | 15.5% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $5.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3M | $1.8M | ||
| Q3 25 | $2.5M | $-2.5M | ||
| Q2 25 | $707.0K | $-654.0K | ||
| Q1 25 | $954.1K | $-7.2M | ||
| Q4 24 | $2.2M | $2.2M | ||
| Q3 24 | $2.4M | $4.2M | ||
| Q2 24 | $1.8M | $-565.0K | ||
| Q1 24 | $-356.9K | $-3.9M |
| Q4 25 | $1.2M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $644.6K | — | ||
| Q1 25 | $892.0K | — | ||
| Q4 24 | $2.1M | $-404.0K | ||
| Q3 24 | $2.3M | $2.8M | ||
| Q2 24 | $21.5K | $-1.0M | ||
| Q1 24 | $-814.6K | $-3.9M |
| Q4 25 | 15.5% | — | ||
| Q3 25 | 31.9% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 11.2% | — | ||
| Q4 24 | 26.8% | -3.2% | ||
| Q3 24 | 27.9% | 16.6% | ||
| Q2 24 | 0.3% | -8.0% | ||
| Q1 24 | -10.4% | -39.9% |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 0.1% | 20.6% | ||
| Q3 24 | 2.3% | 8.3% | ||
| Q2 24 | 21.8% | 3.7% | ||
| Q1 24 | 5.8% | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | 3.38× | — | ||
| Q2 25 | 1.99× | -0.25× | ||
| Q1 25 | 3.37× | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.32× | 1.38× | ||
| Q2 24 | 2.70× | -0.66× | ||
| Q1 24 | -0.64× | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
